Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium‑based contrast agent presented as a solution for injection for intravenous use. It enhances magnetic resonance imaging by increasing signal intensity on T1‑weighted sequences, aiding the diagnosis of liver, cardiovascular, central nervous system and vascular conditions.

GNH USA supplies Multihance as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and imaging centres worldwide.

Multihance (gadobenate dimeglumine) is employed as a gadolinium‑based contrast agent for magnetic resonance imaging procedures.

- Liver MRI: improves detection and characterization of focal hepatic lesions. - Cardiovascular MRI: enhances visualization of myocardial perfusion and vascular anatomy. - Central nervous system MRI: provides clearer delineation of brain tumors and inflammatory lesions. - Magnetic resonance angiography (MRA): increases contrast of arterial and venous structures for detailed vascular assessment.

Multihance may cause a range of adverse reactions following intravenous administration.

Common Side Effects: - Nausea: mild to moderate feeling of stomach upset. - Headache: transient discomfort often reported during or after injection. - Injection site discomfort: pain or burning sensation at the cannula site. - Warmth sensation: brief feeling of heat spreading through the body. - Dizziness: occasional light‑headedness shortly after dosing.

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis: rapid onset of breathing difficulty, rash, or swelling. - Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment. - Cardiovascular collapse: rare episodes of hypotension or cardiac arrest. - Pulmonary edema: fluid accumulation in the lungs, observed in susceptible individuals. - Renal failure exacerbation: worsening of pre‑existing kidney dysfunction.

Prior to using Multihance, clinicians should evaluate patient-specific risk factors and follow recommended handling procedures.

- Renal function assessment: verify glomerular filtration rate before administration. - History of allergic reactions: screen for prior gadolinium or contrast agent hypersensitivity. - Pregnancy considerations: use only if the diagnostic benefit outweighs potential fetal risk. - Breastfeeding guidance: advise caution and consider temporary cessation of nursing. - Severe renal impairment: avoid or use with extreme caution due to NSF risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance can interact with other agents that affect renal function or gadolinium clearance.

Major Interactions (Avoid): - Concurrent administration of other gadolinium‑based contrast agents: may increase cumulative gadolinium exposure and toxicity. - High‑dose iron chelation therapy: can alter gadolinium binding and clearance.

Moderate Interactions (Monitor Closely): - Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): monitor renal parameters closely. - Diuretics: may affect fluid balance and gadolinium distribution. - Beta‑blockers or antihypertensives: observe cardiovascular status during injection. - Radiopharmaceuticals: coordinate timing to avoid overlapping contrast effects.